Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 years and older
• All sexes
• No healthy volunteers
• Adult, Older adult

Trial locations and contacts

1 site in 1 country.

About this study

Official title: Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids.

Conditions

Keloids

Being tested

Bevacizumab, Triamcinolone Acetonide

Medical subject headings

Keloid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• BevacizumabDrug

  anti-VEGF

• Triamcinolone AcetonideDrug

  corticosteroid

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Modified Vancouver scar scale (mVSS)

   Six characteristics of the scar were assessed. These are: vascularity, height, pliability, and pigmentation, pain and pruritis. Each characteristic is given a score, which are added together to give an overall score between 0 and 18. Higher scores mean a worse outcome.

   Measured: 6 months

2. Erythema Index

   Evaluation of skin erythema index was done using a spectrophotometry device

   Measured: 6 months

3. Vascular Endothelial growth factor (VEGF)

   Tissue levels of VEGF, collagen type 1 and 3 measured by Enzyme linked immunosorbent assay

   Measured: 6 months

4. Collagen type 1 and 3

   Tissue levels of collagen type 1 and 3 measured by Enzyme linked immunosorbent assay

   Measured: 6 months

5. Histopathological examination

   Two mm punch biopsies were obtained per area at baseline and one month after the last treatment session. The post-treatment biopsy 3as taken from the vicinity of the baseline biopsy. Tissues are fixed in 10% buffered formalin, embedded in paraffin and sectioned into 5 μm-thick sections. Specimens were stained with hematoxylin and eosin (H\&E) and orcein (or demonstration of elastic fibers). Histological examination was carried out under a light microscopy. Assessment was done as follows:

   1. Assessment of the collagen fibers will be done by examining H \& E slides, putting grading from 1 to 4 according to the thickness and orientation of the collagen fibers and the spaces in between the fibers.
   2. Assessment of the elastic fibers will be done through examining orcein stained specimens and grading the elastic fibers in the scars from 1 to 4 based on presence or absence of the elastic fiber and degree of degradation and fragmentation.

   Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted10 Jun 2025
2. Study start1 Sep 2023
3. Primary completion1 Sep 2024
4. Study completion1 Jul 2025 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Publications (1)Papers the sponsor has linked to this study.
• Other trials for KeloidsStudies of the same condition, open and under way.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.